The company launched in 2023 with $90 million in funding from organizations including Johnson & Johnson’s venture capital arm.

The newly developed urine test helps identify which prostate cancer patients need a biopsy and which can safely skip the ...

A new urine test performed better than PSA-based testing and MRI for monitoring low-risk prostate cancers on active ...

In addition to this license involving PSA velocity, 20/20 Biolabs and Dr. Hébert anticipate conducting joint research to develop similar velocity algorithms for other protein tumor markers like CA 125 ...

The duo stepped out for a dog-related charity event.

The King unveiled a plaque marking the 300th anniversary of Guy’s Hospital.

Q1 2026 earnings call recap: record $17.8M revenue, Focal One HIFU growth, guidance reiterated, risks (tariffs/cash).

As of Tuesday, May 12, PDS Biotechnology Corporation’s PDSB share price has dipped by 11.54%, which has investors questioning ...

The FDA has cleared ArteraAI Breast, the first digital pathology-based risk stratification tool for breast cancer. The AI software analyzes tumor tissue images and clinical data to categorize ...

Cancer research has come in many forms over the years, including the use of AI. In 2026 alone, AI has come a long way as a ...

Good afternoon, ladies and gentlemen, and welcome to the Profound Medical Q1 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Thursday, May 7, 2026. I ...